CoChat
Sign Up
Cited by 76

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Chitosan coated vancomycin hydrochloride liposomes: Characterizations and evaluation

Yang, Zhenlei, Liu, Junli, Gao, Jinhua, Chen, Shilei, Huang, Guihua·2015·International Journal of Pharmaceutics
DOI 10.1016/j.ijpharm.2015.08.085
Open this paper in CoChat — free account

Abstract

The present work evaluated the feasibility of chitosan coated liposomes (c-Lips) for the intravenous delivery of vancomycin hydrochloride (VANH), a water-soluble antibiotic for the treatment of gram-positive bacterial infections like osteomyelitis, arthritis, endocarditis, pneumonia, etc. The objective of this research was to develop a suitable drug delivery system in vivo which could improve therapeutic efficacy and decrease side effects especially nephrotoxicity. Firstly, the vancomycin hydrochloride liposomes (VANH-Lips) were prepared by modified reverse phase evaporation method, then the chitosan wrapped vancomycin hydrochloride liposomes (c-VANH-Lips) nanosuspension was formulated by the method of electrostatic deposition. Based on the optimized results of single-factor screening experiment, the c-VANH-Lips were found to be relatively uniform in size (220.40 ± 3.56 nm) with a narrow polydispersity index (PI) (0.21 ± 0.03) and a positive zeta potential (25.7 ± 1.12 mV). The average drug entrapment efficiency (EE) and drug loading (DL) were 32.65 ± 0.59% and 2.18 ± 0.04%, respectively. The in vitro release profile of c-VANH-Lips possessed a sustained release Characterization and the release behavior was in accordance with the Weibull equation. Hemolysis experiments showed that its intravenous injection had preliminary safety. In vivo, after intravenous injection to mice, c-VANH-Lips showed a longer retention time and higher AUC values compared with the VANH injection (VANH…

Overview

Integrity signals

Registry

Crossref · 10.1016/j.ijpharm.2015.08.085

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 2 references

Research works printed but not linked: 28

  1. Alipsour, 2008, Antimicrobial effectiveness of lipsosomal polymyxin B against resistant gram-negative bacterial strains, Int. J. Pharm., 355, 293, 10.1016/j.ijpharm.2007.11.035 · DOI
  2. Aspden, 1997, Chitosan as a nasal delivery system: the effect of chitosan solutions on in vitro and in vivo mucociliary transport rates in human turbinates and volunteers, J. Pharm. Sci., 86, 509, 10.1021/js960182o · DOI
  3. Banakar, 1997, Advances and opportunities in delivery of therapeutic proteins and peptides, J. Biomater. Appl., 11, 377, 10.1177/088532829701100402 · DOI
  4. Beenken, 2014, Chitosan coating to enhance the therapeutic efficacy of calcium sulfate-based antibiotic therapy in the treatment of chronic osteomyelitis, J. Biomater. Appl., 29, 514, 10.1177/0885328214535452 · DOI
  5. Chun, 2013, Formation and stability of multiple-layered lipsosomes by layer-by-layer electrostatic deposition of biopolymers, Food Hydrocoll., 30, 249, 10.1016/j.foodhyd.2012.05.024 · DOI
  6. Darley, 2004, Antibiotic treatment of gram-positive bone and joint infections, J. Antimicrob. Chemother., 53, 928, 10.1093/jac/dkh191 · DOI
  7. Dieterich, 2009, Gene expression analysis reveals new possible mechanisms of vancomycin-induced nephrotoxicity and identifies gene markers candidates, Toxicol. Sci., 107, 258, 10.1093/toxsci/kfn203 · DOI
  8. Huang, 2010, The role of carrier size in the pharmacodynamics of antisense and siRNA oligonucleotides, J. Drug Target., 18, 567, 10.3109/10611861003734019 · DOI
  9. Huang, 2011, N-trimethyl chitosan-modified lipsosomes as carriers for oral delivery of salmon calcitonin, Drug Deliv., 18, 562, 10.3109/10717544.2011.596585 · DOI
  10. Huh, 2011, Nanoantibiotics: a new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant era, J. Control. Release, 156, 128, 10.1016/j.jconrel.2011.07.002 · DOI
  11. Janes, 2001, Polysaccharide colloidal particles as delivery systems for macromolecules, Adv. Drug Deliv. Rev., 47, 83, 10.1016/S0169-409X(00)00123-X · DOI
  12. Kadry, 2004, Treatment of experimental osteomyelitis by liposomal antibiotics, J. Antimicrob. Chemother., 54, 1103, 10.1093/jac/dkh465 · DOI
  13. Kinik, 2008, Cierny-mader type III. Chronic osteomyelitis: the results of patients treated with debridement, irrigation, vancomycin beads and systemic antibiotics, Int. Orthop., 32, 551, 10.1007/s00264-007-0342-9 · DOI
  14. Laye, 2008, Formation of biopolymer-coated liposomes by electrostatic deposition of chitosan, J. Food Sci., 73, N7, 10.1111/j.1750-3841.2008.00747.x · DOI · Paper page
  15. Lew, 2004, Osteomyelitis, Lancet, 364, 369, 10.1016/S0140-6736(04)16727-5 · DOI
  16. Liu, 2014, Quantitative evaluation of the reticuloendothelial system function with dynamic MRI, PLoS One, 9, e103576, 10.1371/journal.pone.0103576 · DOI
  17. Liu, 2015, Lipsosomes for systematic delivery of vancomycin hydrochloride to decrease nephrotoxicity: characterization and evaluation, Asian J. Pharm. Sci., 10, 212, 10.1016/j.ajps.2014.12.004 · DOI
  18. Ma, 2011, Nano-hydroxyapatite/chitosan/konjac glucomannan scaffolds loaded with cationic liposomal vancomycin: preparation, in vitro release and activity against Staphylococcus aureus biofilms, J. Biomater. Sci. Polym. Ed., 22, 1669, 10.1163/092050611X570644 · DOI
  19. Mader, 1999, Antimicrobial treatment of chronic osteomyelitis, Clin. Orthop. Relat. Res., 360, 47, 10.1097/00003086-199903000-00008 · DOI
  20. Moghimi, 2001, Long-circulating and target-specific nanoparticles: theory to practice, Pharmacol. Rev., 53, 283, 10.1016/S0031-6997(24)01494-7 · DOI
  21. Muppidi, 2011, PEGylated liposome encapsulation increases the lung tissue concentration of vancomycin, Antimicrob. Agents Chemother., 55, 4537, 10.1128/AAC.00713-11 · DOI
  22. Ruozi, 2011, AFM, ESEM, TEM, and CLSM in lipsosomal characterization: a comparative study, Int. J. Nanomed., 6, 557, 10.2147/IJN.S14615 · DOI
  23. Rybak, 2006, The pharmacokinetic and pharmacodynamic properties of vancomycin, Clin. Infect. Dis., 42, S35, 10.1086/491712 · DOI
  24. Sandri, 2004, Assessment of chitosan derivatives as buccal and vaginal penetration enhancers, Eur. J. Pharm. Sci., 21, 351, 10.1016/j.ejps.2003.10.028 · DOI
  25. Van Hoesel, 1984, Reduced cardiotoxicity and nephrotoxicity with preservation of antitumor activity of doxorubicin entrapped in stable lipsosomes in the LOU/M Wsl rat, Cancer Res., 44, 3698
  26. Walter, 2012, Treatment algorithms for chronic osteomyelitis, Deutsch. Ärzteb. Int., 109, 257
  27. Yang, 2012, A practical model of osteomyelitis-induced bone pain by intra-tibial injection of Staphylococcus aureus in rats, Neurosci. Lett., 513, 198, 10.1016/j.neulet.2012.02.038 · DOI
  28. Yang, 2013, Preparation of cationic vancomycin hydrochloride multivesicular liposomes and its quality, Chin. J. Repar. Reconstr. Surg., 27, 443

Cited by

Sorted by citations

Metadata

Authors
Yang, Z., Liu, J., Gao, J., Chen, S., & Huang, G.
Venue
International Journal of Pharmaceutics
Publisher
Elsevier BV
Published
2015-11
Volume
495
Issue
1
Pages
508-515
ISSN
0378-5173
DOI
10.1016/j.ijpharm.2015.08.085
Cited by
76
References
2
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review